Bachelor of Science

Caledonia Mining Corporation Plc: Appointment of Chief Operating Officer

Retrieved on: 
Monday, April 8, 2024
The Company, Ageing, Gold, Bachelor of Science, Copper, MBA, Nickel, Harmony Gold (mining), Region, Harmony Gold, Bilboes, Mining engineering, Blanket, Mining

ST HELIER, Jersey, April 08, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or the "Company") (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) is pleased to announce that James Mufara (aged 49) has agreed to join the Caledonia group as Chief Operating Officer with effect from May 1, 2024.

Key Points: 
  • ST HELIER, Jersey, April 08, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or the "Company") (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) is pleased to announce that James Mufara (aged 49) has agreed to join the Caledonia group as Chief Operating Officer with effect from May 1, 2024.
  • James was previously at Harmony Gold Mining Company Limited where, as Regional General Manager, he headed a complex portfolio of operations consisting of five mines and 15,000 staff, mining 450koz of gold per annum.
  • James has over 25 years’ experience in the mining sector in Southern Africa, including 13 years in leadership roles.
  • His career has been primarily gold focused, but also with exposure to nickel, copper, and chrome mining.

Koryx Copper Intersects 168.60 Metres at 0.40% Cu Eq Including Multiple 2 m Intersections >1.00% Cu Eq and 34.00 m at 0.73% Cu Eq Including 2 m at 2.28% Cu Eq

Retrieved on: 
Thursday, April 4, 2024
Element, Quality control, Molybdenum, National Instrument 43-101, Mineral Resources Limited, ALS, ICP, Copper, Bachelor of Science, Gold, News, Laboratory, Geology, National instrument, Qualified person (European Union), Honours degree, Planview, Road

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Koryx Copper Inc. ("Koryx" or “the Company") (TSX-V: KRY) announces the third assay results from its current drilling program at its Haib Copper project in southern Namibia.  The Company’s latest four drill holes continue to confirm that the deposit can deliver high grades over substantial widths within the known historical resource.

Key Points: 
  • CuEq (copper equivalent) has been used to express the combined value of copper and molybdenum and is provided for illustrative purposes only.
  • Also half-way up the southern slope it too was positioned to close the sample spacing in this part of Pit1.
  • HM39 was drilled west of and parallel to HM34 and was positioned to close the sample spacing in this direction.
  • Over time, it has seen several transformations including shearing and faulting events that appear to have further concentrated Cu and Mo.

Former CEOs of JetBlue, Maersk Drilling, and Public Service Enterprise Group (PSEG) join Avina Clean Hydrogen’s distinguished advisory board

Retrieved on: 
Wednesday, April 3, 2024
Hydrogen, Physics, Maersk Drilling, University, AP, BP, Advisory board, U.S. Steel, Electronic, Steel, Independent, Copenhagen Business School, Bachelor of Science, Aviation, Columbia University, Public Service Enterprise Group, Risk intelligence, Robin, MBA, Doctor of Philosophy, JetBlue, CSR, Former, Electrical engineering, Maersk, Engineering, Management

SHORT HILLS, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Avina Clean Hydrogen is excited to announce the appointment of three renowned industry leaders to its Advisory Board.

Key Points: 
  • SHORT HILLS, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Avina Clean Hydrogen is excited to announce the appointment of three renowned industry leaders to its Advisory Board.
  • Ltd., and Ralph Izzo, Former Chairman and CEO of Public Service Enterprise Group (PSEG), join the existing distinguished panel of advisory board members, bringing valuable expertise and insight to the company's projects in the clean fuels sector.
  • "We are thrilled to welcome our new Advisory Board members," said Vishal Shah, Founder & CEO of Avina Clean Hydrogen.
  • Their expertise will complement our existing prestigious Advisory Board members, enabling us to collaborate effectively in building a world-class company that delivers compelling clean fuel solutions to the market,” said Steven Berkenfeld, Board Member of Avina.

ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

Retrieved on: 
Tuesday, April 2, 2024
Clinical research, Molecular medicine, AstraZeneca, Entrepreneurship, Patient, SAN, Mayo Clinic, Research, RNA, Bachelor of Science, Lead, University, MD, Senior, Sympathetic nervous system, Biology, Therapy, Destiny, Division, CMO, Amgen, DSM-IV codes, Pharmaceutical industry

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics, Pharmacovigilance and Medical Affairs.
  • Dr. Storgard has a BSc in biology and an MD from the University of Saskatchewan in Canada.
  • Dr. Storgard completed a fellowship in rheumatology at Scripps Clinic and Research Center in San Diego, CA.

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Seek Labs Welcomes Esteemed Diagnostics Industry Innovator and Executive, Dr. Randy Rasmussen, PhD, to Board of Directors

Retrieved on: 
Friday, March 29, 2024
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Growth, Infection, JPMorgan Chase, Knowledge, Bachelor of Science, Sale, Acquisition, University, IPO, Doctor of Philosophy, Utah State University, Molecular biology, Publication, CRISPR, Management

Having amassed a remarkable track record of advancements in molecular diagnostic technologies throughout his career, Dr. Rasmussen is a highly regarded figure in the field of molecular diagnostics.

Key Points: 
  • Having amassed a remarkable track record of advancements in molecular diagnostic technologies throughout his career, Dr. Rasmussen is a highly regarded figure in the field of molecular diagnostics.
  • "We are delighted to welcome Randy Rasmussen to Seek Labs’ Board of Directors," said Jared Bauer, CEO.
  • Dr. Rasmussen expressed his excitement to join Seek Labs’ Board and contribute to the company’s success: “Seek Labs’ commitment to molecular diagnostic innovation aligns with my own passion for diagnostic innovation and improving healthcare outcomes.
  • Dr. Rasmussen currently serves as Chairman of the Board for BioUtah and as a Board Member for Quansys Biosciences.

Rasmussen University Centralizes Ocala Operations into One Location, Begins Classes in Newly Expanded Campus

Retrieved on: 
Thursday, April 4, 2024
Online, Environment, Associate, Education, Simulation, University, Rasmussen University, Physical therapy, Student, Bachelor, Bachelor of Science, Nursing, School

OCALA, Fla., April 4, 2024 /PRNewswire/ -- Rasmussen University today announced the completion of its campus consolidation and centralization efforts in Ocala, which includes an expansion to its campus located at 1227 SW 17th Avenue.

Key Points: 
  • Last fall, Rasmussen announced plans to consolidate its Main and School of Nursing campus operations into a single location, specifically at its nursing campus location, while also expanding the footprint of the nursing campus.
  • Rasmussen began its Spring Quarter this week under one roof at what is now known as the Rasmussen University Ocala campus .
  • "We are thrilled to welcome students, particularly our radiologic technology and medical assisting students, as they join our nursing students at our newly expanded Ocala campus," said Pete Beasley, senior campus executive director, Rasmussen University—Ocala campus.
  • For more information about the Rasmussen University Ocala campus, please visit https://www.rasmussen.edu/locations/florida/ocala/ .

Alexion Canada Appoints Karen Heim as New General Manager

Retrieved on: 
Tuesday, April 2, 2024
Circulatory system, Neurology, AstraZeneca, GSK plc, Metabolism, Hematology, Cardiology, Patient, DSM-IV codes, Research, Alexion Pharmaceuticals, Bachelor of Science, Acquisition, University, Senior, Metallurgy, Nephrology, Queen's University, Rare disease, Immunity (medical), Alexion, Ophthalmology, Pharmaceutical industry

MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

Key Points: 
  • MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
  • In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
  • "Karen's deep healthcare experience and incredible passion make her the perfect fit to lead this mission in Canada and drive it with expertise and ambition."
  • "Taking on this leadership role at Alexion Canada as it continues to grow, with a focus on research and innovation, is incredibly exciting," says Ms. Heim.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Former KPMG Chairman and CEO Lynne Doughtie Assumes Role as Chair of LUNGevity's Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Lung cancer, NAF (non-profit organization), Glassdoor, KPMG, Organization, Woman, Virginia Tech, Environment, Disease, Boeing, Research, Top, Quality of life, Bachelor of Science, National Association, Estate (law), Management

WASHINGTON, March 21, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, announced today the appointment of Lynne Doughtie, former KPMG chairman and CEO, as chair of its Board of Directors. Doughtie, who has served as a dedicated member of the LUNGevity Board since 2016, brings a wealth of experience and personal commitment to LUNGevity's mission.

Key Points: 
  • WASHINGTON, March 21, 2024 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, announced today the appointment of Lynne Doughtie, former KPMG chairman and CEO, as chair of its Board of Directors.
  • Doughtie, who has served as a dedicated member of the LUNGevity Board since 2016, brings a wealth of experience and personal commitment to LUNGevity's mission.
  • In 2015, she became the first woman to be elected chairman and CEO of KPMG, where she spearheaded the firm's growth and innovation, leading a team of over 29,000 professionals.
  • "We are thrilled to welcome Lynne as chair of our Board of Directors," said Andrea Ferris, president and CEO of LUNGevity Foundation.